Short answer
Inmune Bio, Inc. (INMB) filed an 8-K current report with the SEC on July 31, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Australia R&D cash rebate of approximately $4.2 million received July 30, 2026.
Inmune Bio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Australia R&D cash rebate of approximately $4.2 million received July 30, 2026
- Non-dilutive cash inflow supporting INmune Bio’s research and development funding
- Press release details attached as Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Approximately $4.6M in non-dilutive R&D rebates received from Australia and the UK during June–July 2026
- Australia rebate approximately $4.2M received July 30, 2026; UK rebate approximately $0.4M received during June
- Combined proceeds exceeded second-quarter net cash used in operating activities after excluding the UK rebate
- Improved liquidity and extended cash runway without additional equity issuance
- Funding supports CORDStrom’s planned UK MHRA filing in 2026 and broader regulatory milestones
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Inmune Bio, Inc. 8-K filings
Get the next INMB 8-K as it lands
Follow INMB for push alerts, or ask the research agent what this filing means.